Brief Online Resources for Teaching Neuroscience: Impact on Attitudes, Stigma, and Clinical Practice Among Mental Health Professionals.

Acad PsychiatryMar 18, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Melissa R Arbuckle, Kathleen Ferreira, Evan J Kyzar et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated brief online neuroscience learning resources among 120 mental health professionals, including psychiatrists, psychologists, nurses, counselors, and social workers. Participants were assigned to active learning or a lagged-start waitlist, with learning and consolidation phases. At 3 months, compared with the waitlist group, the active group reported more positive attitudes toward neuroscience (p = 0.028) and higher Medical Condition Regard Scale scores (p = 0.001), but there was no significant between-group difference in applying neuroscience to practice. After both groups completed consolidation, the combined cohort showed significant increases across all three measures.

Key findings

  • At 3 months, the active group had more positive neuroscience attitudes than the waitlist group (p = 0.028).
  • Medical Condition Regard Scale scores were higher in the active group than the waitlist group at 3 months (p = 0.001).
  • There was no significant between-group difference in application of neuroscience to practice at 3 months.
  • After consolidation, the combined cohort showed significant increases across attitudes, practice application, and regard for patients with mental illness.

Why it matters

The findings suggest that brief online educational resources can influence mental health professionals’ attitudes toward neuroscience and people with mental illness. The lack of a significant early between-group difference in practice application is important: improved attitudes do not necessarily translate immediately into reported clinical use. The later combined-cohort changes support further consideration of sustained learning, while not establishing which resources or learning components drove the changes.

What to keep in mind

The abstract does not report effect sizes or the magnitude of changes. The 9-month findings are from the combined cohort after both groups received learning, so they do not provide a concurrent untreated comparison.

Source

Published in Acad Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.